Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI

Medical Oncology

Volumn 29, Issue 5, 2012, Pages 3291-3297

  Park, Kwonoh ^a   Lee, Jae Lyun ^a   Park, Inkeun ^a   Park, Seongjoon ^a   Ahn, Yongcheol ^a   Ahn, Jin Hee ^a   Ahn, Shin ^a   Song, Cheryn ^a   Hong, Jun Hyuk ^a   Kim, Choung Soo ^a   Ahn, Hanjong ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Everolimus; Renal cell carcinoma; Sequential therapy; Sorafenib; Sunitinib; Temsirolimus

Indexed keywords

CALCIUM; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; EGFR PROTEIN, HUMAN; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; INDOLE DERIVATIVE; NICOTINAMIDE; PROTEIN TYROSINE KINASE; PYRROLE DERIVATIVE; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS RESECTION; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; COMPARATIVE STUDY; DRUG ANTAGONISM; KAPLAN MEIER METHOD; KIDNEY TUMOR; METHODOLOGY; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; SALVAGE THERAPY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROPORTIONAL HAZARDS MODELS; PROTEIN-TYROSINE KINASES; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SALVAGE THERAPY; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84880267774     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0227-7     Document Type: Article

References (24)

1. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125-34.
2. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103-11.
3. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-81.
4. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449-56.
5. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-24.
6. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26(33):5422-8.
7. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061-8.
8. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer. 2009;115(1):61-7.
9. Eichelberg C, Heuer R, Chun FK, Hinrichs K, Zacharias M, Huland H, et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol. 2008;54(6):1373-8.
10. Sablin MP, Negrier S, Ravaud A, Oudard S, Balleyguier C, Gautier J, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol. 2009;182(1):29-34.
11. Di Lorenzo G, Carteni G, Autorino R, Bruni G, Tudini M, Rizzo M, et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol. 2009;27(27):4469-74.
12. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009;27(27):4462-8.
13. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931-9.
14. Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C, et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol. 2008;61(3):515-24.
15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.
16. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794-9.
17. Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2009;7(1):24-7.
18. Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(9):1432-9.
19. Negrier S, Gravis G, Perol D, Chevreau C, Delva R, Bay JO, et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol. 2011;12(7):673-80.
20. Herrmann E, Marschner N, Grimm MO, Ohlmann CH, Hutzschenreuter U, Overkamp F, et al. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. World J Urol. 2011;29(3):361-6.
21. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26(1):127-32.
22. Schmidinger M, Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev. 2010;36(5):416-24.
23. Heng DY, Mackenzie MJ, Vaishampayan UN, Bjarnason GA, Knox JJ, Tan MH, et al. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann Oncol. 2011;Nov 5:[Epub ahead of print].
24. Clinicalconnection. A randomized trial of temsirolimus versus sorafenib as second-line therapy in patients with advanced renal cell carcinoma who have failed first-line sunitinib therapy. Clinicalconnection. 2012. http://75.126.186.193/exp/EPVS.aspx?studyID=240312&slID=448904. Accessed 22 Nov 2011.